Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AllocetraTM in Age-Related Knee Osteoarthritis
· enlivex ltd.
AI Briefing
- • Enlivex Ltd. receives FDA RMAT designation for AllocetraTM in age-related knee osteoarthritis treatment.
- • AllocetraTM is for symptomatic knee OA in patients aged 64 and older.
- • Designation accelerates Enlivex's clinical trials and potential approval process.
Source Summary
Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to AllocetraTM, the Company's clinical-stage immunotherapy, for the treatment of age-related symptomatic knee osteoarthritis (OA) in patients aged 64 and older.
Advertisement